Clinical Trial Update: Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial is evaluating the combination of irinotecan, POF (POFI), and tislelizumab for stage IV gastric cancer. The study is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• POF (POFI)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Gastric Cancer Stage IV | Phase 1, Phase 2 | Status: RECRUITING